What Intas Pharmaceuticals does

Intas Pharmaceuticals Ltd. is an Ahmedabad-headquartered, privately held Indian multinational pharmaceutical formulation development, manufacturing, and marketing company operating across 85+ countries. Its portfolio spans small-molecule generics across CNS, cardiovascular, diabetology, gastroenterology, urology, oncology, hematology, immunology, and neurology; a growing biosimilars franchise referencing rituximab, bevacizumab, trastuzumab, filgrastim, pegfilgrastim, golimumab, and ustekinumab (commercialized in the US through Accord BioPharma and in Europe through Accord Healthcare); plasma-derived products including albumin, immunoglobulins, and clotting factors; cell and gene therapy programs (the first in India) covering blood disorders, tumours, blindness, and muscular dystrophies; and respiratory devices under the QUIKHALER brand. Manufacturing spans 17 advanced facilities with WHO GMP, EU GMP, ANVISA, CDSCO, GCC, and SAHPRA certifications, plus a recently acquired plasma fractionation asset in Belgium via Prothya Biosolutions.

The business model combines direct field sales through wholly-owned subsidiaries in regulated markets (Accord Healthcare in UK/EU as the #1 UK generic company, Accord BioPharma in the US for biosimilars) with channel-partner and distributor coverage across emerging markets in Asia, Africa, and Latin America. Revenue is generated primarily through unit pricing of finished formulations sold to hospitals, government healthcare systems, retail pharmacies, and institutional buyers, with contract manufacturing as a secondary stream and biosimilars distributed via licensed partners outside core territories. Approximately 70% of revenue is international and the company cites a 22% growth rate, with the plasma business compounding at ~30% CAGR.

Strategic activity in 2025-2026 is heavily weighted to biosimilars and plasma: the USD 558.4 million acquisition of Coherus' Udenyca franchise (August 2025) made Accord BioPharma one of the world's largest pegfilgrastim suppliers; the Prothya Biosolutions acquisition (October 2025) extended European plasma reach; multiple licensing deals added serplulimab (Henlius), etanercept (mAbxience), and nivolumab biosimilar (Xbrane) to the immuno-oncology and immunology pipelines; and FDA-approved launches of FILKRI, IMULDOSA, and HERCESSI expanded the US biosimilar portfolio. The same period also brought a USFDA warning letter for the Dehradun plant (March 2026) citing data integrity and quality issues, a material regulatory overhang on the US business that investors must weigh against the otherwise aggressive expansion trajectory.

Name

Intas Pharmaceuticals

Legal name

Intas Pharmaceuticals Ltd.

Website

https://intaspharma.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Intas Pharmaceuticals is an Indian-headquartered global pharmaceutical company developing, manufacturing, and marketing generics, biosimilars, plasma-derived therapies, and cell and gene therapies across 85+ countries, primarily serving hospitals, government health systems, and distributors via its Accord Healthcare and Accord BioPharma subsidiaries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceuticals
• Biosimilar development
• Plasma fractionation
• Cell gene therapy
• Pharmaceutical manufacturing

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Revenue from manufacturing and selling generic pharmaceutical formulations including tablets, capsules, injectables across multiple therapeutic areas. Approximately 70% of revenues come from international markets.
2. Biosimilars: Revenue from biosimilar products including oncology (bevacizumab, trastuzumab, rituximab), autoimmune, and supportive care (filgrastim, pegfilgrastim). Products commercialized through Accord BioPharma in US and Accord Healthcare in Europe.
3. Plasma-Derived Products: Revenue from plasma fractionation products including human albumin, immunoglobulins, factor VIII, factor IX, fibrinogen, and prothrombin complex. Growing at 30% CAGR.
4. Acquisition/Udenyca Franchise: $558.4 million acquisition of Udenyca franchise from Coherus BioSciences in August 2025, expanding pegfilgrastim biosimilar portfolio
5. Contract Manufacturing: Pharmaceutical contract manufacturing services with cGMP compliant facilities serving other pharmaceutical companies

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Intas Pharmaceuticals develops, manufactures, and markets a broad portfolio of pharmaceutical formulations including generic drugs (tablets, capsules, injectables), biosimilars (rituximab, bevacizumab, trastuzumab, filgrastim, pegfilgrastim, golimumab, ustekinumab), plasma-derived products (albumin, immunoglobulins, clotting factors), and cell & gene therapies for global markets across 85+ countries.

Product overview

Intas Pharmaceuticals is a multinational pharmaceutical formulation development, manufacturing, and marketing company offering a diverse portfolio of products across multiple therapeutic segments. The company provides formulations ranging from tablets and capsules to injectables and newer biologic therapies, with a strong presence in international markets particularly the EU and US. The portfolio includes: generics across CNS, cardiovascular, diabetology, gastroenterology, urology, oncology, hematology, immunology, and neurology; biologic products including biosimilars (bevacizumab, rituximab, trastuzumab, filgrastim, pegfilgrastim, golimumab, ustekinumab); plasma-derived products (immunoglobulins, albumin, clotting factors, fibrinogen); respiratory devices (QUIKHALER inhaler series); and AI-powered technology platforms (AIMY HR assistant and Intas Insights customer engagement). The company operates through subsidiaries including Accord Healthcare (global generics), Accord BioPharma (US specialty), and Accord Plasma (plasma therapies), with R&D investment of 6-7% of turnover supporting over 10,000 product registrations worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Accord Healthcare: Global pharmaceutical operations brand for Intas, covering European, UK and international markets
• Accord BioPharma
• Accord Plasma

Products and services

• Amtas Amlodipine besylate tablet for cardiovascular care, specifically formulated for hypertension management.
• Bevatas Bevacizumab recombinant anti-cancer biosimilar for treating various cancers including colorectal, lung, breast, kidney, and ovarian cancers.
• Ceftas Cefixime antibiotic formulation for treating bacterial infections.
• Clavix Clopidogrel bisulfate antiplatelet agent for cardiovascular disease prevention.
• Cloba Clobazam anxiolytic medication for anxiety and seizure disorders.
• Divaa Divalproex sodium extended-release formulation for epilepsy and bipolar disorder treatment.
• ELEFTHA Trastuzumab recombinant biosimilar for HER2-positive breast cancer and metastatic gastric cancer treatment.
• Epofit Epoetin alfa recombinant erythropoiesis-stimulating agent for anemia treatment in chronic kidney disease and oncology patients.
• Factocel VIII Dried human anti-hemophilic factor VIII for hemophilia A treatment.
• Factocel IX Freeze-dried human coagulation factor IX for hemophilia B treatment.
• Fibrogen I Human fibrinogen for fibrinogen deficiency and bleeding disorders treatment.
• Folisurge FSH (follicle-stimulating hormone) for infertility treatment.
• Gabapin NT Gabapentin and nortriptyline combination for neuropathic pain management.
• Globucel Human normal immunoglobulin for intravenous use for immune deficiency and autoimmune disorders.
• Globucel-SC Subcutaneous human immunoglobulin for primary immunodeficiency treatment.
• Globucel-VF High-dose intravenous immunoglobulin for neurological disorders and immune deficiencies.
• Hifenac P Aceclofenac and paracetamol combination analgesic for pain and inflammation.
• IntaGlob Human normal immunoglobulin for intramuscular use.
• Levera Levetiracetam antiepileptic drug for seizure management.
• Lipicure Atorvastatin calcium for hyperlipidemia and cardiovascular risk reduction.
• Looz Lactulose solution for constipation and hepatic encephalopathy.
• Mabtas Rituximab recombinant biosimilar for B-cell lymphoma and autoimmune diseases.
• Pro-throm Freeze-dried human prothrombin complex for coagulation factor deficiency.
• Rabium Rabeprazole sodium proton pump inhibitor for acid-related disorders.
• ROMY Romiplostim recombinant thrombopoietin receptor agonist, first launched in India for chronic immune thrombocytopenia (ITP) therapy.
• Terifrac Teriparatide recombinant for osteoporosis treatment, also available as Terifrac Multi for bone disorders.
• Thymotas Patented immuno-booster add-on to standard COVID-19 treatment.
• Valprol Valproic acid/valproate formulation for epilepsy, bipolar disorder, and migraine prophylaxis.
• Veltam Tamsulosin hydrochloride alpha-blocker for benign prostatic hyperplasia.
• Zenoxa Oxcarbazepine antiepileptic for seizure control.
• Zoryl M Glimepiride and metformin combination for type 2 diabetes management.
• Albucel Human normal albumin solution used for plasma volume expansion and hypoproteinemia treatment.
• FILKRI (filgrastim-laha) FDA-approved filgrastim biosimilar (G-CSF) for reducing neutropenia duration in chemotherapy patients, marking Accord BioPharma's sixth biosimilar.
• HERCESSI (trastuzumab-strf) Trastuzumab biosimilar with preferred formulary status on Express Scripts for HER2-overexpressing breast cancer and metastatic gastric cancer.
• IMULDOSA (ustekinumab-srlf) FDA-approved ustekinumab biosimilar to STELARA for autoimmune disease treatment.
• UDENYCA Pegfilgrastim biosimilar acquired from Coherus BioSciences for infection-prevention in cancer patients undergoing chemotherapy.
• Trastuzumab Biosimilar (India launch) Trastuzumab biosimilar launched for the Indian market to treat HER2-positive cancers.
• Tofacitinib Topical (JAKi) DCGI-approved Tofacitinib Topical (JAKi) for Auto-Immune Condition Atopic Dermatitis (AD) for Indian patients.
• QUIKHALER Inhaler device for respiratory care including formulations for asthma and COPD management.
• QUIKHALE-T Tiotropium bromide inhalation device for COPD maintenance therapy.
• IMMGOLIS (golimumab-sldi)
• ZONALTA (Endoxifen Citrate 8mg) Brand name for endoxifen citrate 8mg product in CNS/neurology therapeutic segment.
• LETHYROX Levothyroxine sodium hormone replacement for hypothyroidism.
• REDEMIDE Thalidomide 50mg for dermatoses including leprosy and multiple myeloma.
• CELESTRASE 1 Human C1-esterase inhibitor for hereditary angioedema treatment.
• COVID-19 Hyperimmune Globulin New treatment approach for COVID-19 using hyperimmune globulin developed by Intas.

Quantifiable outcome

• 30% CAGR in plasma fractionation business
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Atossa TherapeuticsminorStrategic or Co-development Partner · 16 April 2026Settlement agreement in patent dispute related to Endoxifen before the U.S. Patent and Trademark Office Patent Trial and Appeal Board. All parties seek termination of PTAB proceedings with mutual commitments not to challenge certain patents.
• Accord BioPharmacoreChannel Partner/ Reseller/ Distributor · 20 March 2026Accord BioPharma (US subsidiary of Intas) files IPR petitions challenging Janssen golimumab patents and commercializes biosimilars including FILKRI (filgrastim biosimilar), HERCESSI (trastuzumab biosimilar), and IMULDOSA (ustekinumab biosimilar) in the US market.
• Kashiv BioSciencescoreStrategic or Co-development Partner · 10 February 2026Exclusive licensing and supply agreement for a complex peptide product covering pan-European, UK, and Indian markets. Kashiv handles regulatory registration, manufacturing, and supply while Accord Healthcare (Intas subsidiary) manages commercialization and distribution.
• Prothya BiosolutionscoreStrategic or Co-development Partner · 20 October 2025Accord Plasma B.V. (subsidiary of Intas) acquired Prothya Biosolutions Belgium BV and subsidiaries, expanding global plasma therapy capabilities and access to plasma-derived medicines in Europe.
• Bio-Thera SolutionscoreStrategic or Co-development Partner · 10 October 2025Expanded partnership for BAT2506, a proposed biosimilar referencing Simponi (golimumab). Bio-Thera handles development and manufacturing while Intas commercializes in India. This is Bio-Thera's first biosimilar partnership in India and extends to Canada for broader market access.
• Coherus BioSciencescoreStrategic or Co-development Partner · 1 August 2025Intas acquired the UDENYCA product franchise for $558.4 million in August 2025. The acquisition strengthens both companies' positions in the pegfilgrastim biosimilar segment, with Intas forming one of the world's largest pegfilgrastim suppliers through Accord BioPharma.
• Henlius BiotechcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Exclusive license agreement to commercialize serplulimab, an anti-PD-1 monoclonal antibody for cancer treatment, expanding Intas' immuno-oncology portfolio in emerging markets.
• mAbxiencecoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Licensing agreement for Etanercept biosimilar, expanding biosimilar portfolio in immunology segment.
• Xbrane BiopharmacoreStrategic or Co-development Partner · 1 January 2025Global licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo for markets worldwide. Joint development partnership for PD-1 inhibitor biosimilar.
• JM LaboratoriesminorOthersListed among top 10 pharmaceutical contract manufacturers in India alongside Intas Pharmaceuticals. Competitive positioning rather than partnership.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sun Pharmaceutical Industries: Largest pharmaceutical company in India and direct competitor in generics, biosimilars (including competing trastuzumab and bevacizumab products), and specialty therapeutics. Sun Pharma and Intas have directly clashed in trademark litigation (Bevatas vs Bevetex), confirming overlapping product portfolios and competitive positioning in oncology generics.
• Cipla: Major Indian pharmaceutical manufacturer with overlapping respiratory, oncology, and biosimilar portfolios. Both companies face identical NPPA price cap exposure on oncology drugs like cisplatin and carboplatin and compete across emerging market channels and Indian domestic hospital supply.
• Dr. Reddy's Laboratories: Indian multinational pharmaceutical peer with comparable generics, biosimilars, and API manufacturing capabilities. Dr. Reddy's has a similarly broad emerging market and regulated market footprint and competes with Intas across multiple therapeutic categories including oncology and immunology.
• Lupin Limited: Leading Indian pharmaceutical company with comparable generics, complex generics, and biosimilar strategies. Lupin shares Intas's focus on regulated markets (US, EU) and emerging markets, and competes in cardiovascular, CNS, and respiratory therapeutic areas where Intas is also strong.
• Biocon: India's leading biosimilars company and the most direct competitor to Intas's biologics business. Both target global biosimilar markets including trastuzumab, bevacizumab, and other oncology biologics, with overlapping commercialization partnerships in emerging markets.
• Aurobindo Pharma: Indian pharmaceutical manufacturer with major biosimilar and injectable portfolios (via Eugia and CuraTeQ). Aurobindo directly competes with Intas/Accord in the US hospital injectables market and is expanding its biosimilar pipeline across oncology and immunology.
• Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical company with comparable generics, biosimilars (Exemptia, similar to Intas's immunology portfolio), and specialty therapeutics. Zydus competes across multiple therapeutic areas and emerging markets where Intas has presence.

Emerging players

• Coherus BioSciences: US-based biosimilar company that sold its Udenyca (pegfilgrastim) franchise to Intas for $558.4M in August 2025. Coherus and Intas now jointly influence the US pegfilgrastim biosimilar market and Coherus remains a competitor in adjacent biosimilar molecules.
• Bio-Thera Solutions: Chinese biosimilar developer that is both Intas's biosimilar partner (BAT2506/golimumab development and commercialization) and a broader biosimilar competitor. Bio-Thera's first India partnership is with Intas, but its golimumab biosimilar (IMMGOLIS) competes with Intas's other oncology biosimilars globally.

Broad incumbents

• Sandoz Group: Global generics and biosimilars leader (spun off from Novartis) and a broad incumbent in the same industry. Sandoz competes with Intas across global generics and biosimilar markets including oncology, immunology, and supportive care, though as a broader portfolio player rather than a niche specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/intas-pharmaceuticals
• Xx.com/intassupriva

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intas Pharmaceuticals